Guard Therapeutics International AB (SE:GUARD)
:GUARD
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr1.00 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr25.21M
Enterprise Value-kr24.62M
Total Cash (Recent Filing)kr100.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtThe consistent absence of debt materially reduces refinancing and default risk for an early‑stage biotech. With no outstanding borrowings the company has greater strategic flexibility to time equity raises, pursue partnerships or opportunistic licensing without near‑term covenant pressure.
Proprietary A1M PlatformA focused platform around A1M gives a clear scientific differentiation in kidney disease therapeutics. Platform assets can support multiple indications or formulation strategies, attract collaboration partners, and create durable IP value that underpins long‑term commercial optionality if clinical progress continues.
Lean OrganizationA small headcount suggests a lean operating model that can help conserve cash and target spend toward core R&D activities. For a pre‑commercial biotech, disciplined staffing supports capital efficiency and allows management to outsource expensive functions while extending runway between financings.
Bears Say
No RevenueAbsence of any revenue means the firm's value and sustainability hinge entirely on R&D success and external financing. Persistent pre‑revenue status increases execution risk, limits internal funding capacity for development, and raises likelihood of dilutive capital raises if clinical timelines slip.
Heavy Cash BurnSustained large negative operating cash flow rapidly consumes resources and shortens the firm's financing runway. Given volatile and large outflows, management faces ongoing pressure to secure capital, which can force dilution, delay programs, or shift priorities away from high‑value but longer‑dated indications.
Weakened Balance SheetSharp depletion of assets and equity erodes the company's financial buffer and reduces capacity to absorb further losses or adverse trial outcomes. A thinner balance sheet limits strategic options, increases vulnerability to unfavorable financing terms, and heightens restructuring or discontinuation risk if funding becomes constrained.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr1.00 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr25.21M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -kr0.81 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.81.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―